The recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
Vijesh Unnikrishnan and Ganesh Vedarajan
Advertisement
Vijesh Unnikrishnan is a principal in ZS’s digital and connected health (DCH) practice. Ganesh Vedarajan leads ZS’s strategy and transformation practice.
Articles by Vijesh Unnikrishnan and Ganesh Vedarajan
Advertisement
Latest Updated Articles
- The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian Moment
Published: September 8th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
